Histone deacetylase inhibitors equipped with estrogen receptor modulation activity

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5782-5796

  Gryder, Berkley E ^a   Rood, Michael K ^a   Johnson, Kenyetta A ^a   Patil, Vishal ^a   Raftery, Eric D ^a   Yao, Li Pan D ^a   Rice, Marcie ^a   Azizi, Bahareh ^a   Doyle, Donald F ^a   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 ETHYNYLBENZYL)TAMOXIFEN; 4 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY) N HYDROXYBUTANAMIDE; 4 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY)BUTANAMIDE; 5 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY) N HYDROXYPENTANAMIDE; 5 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY)PENTANAMIDE; 6 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY) N HYDROXYHEXANAMIDE; 6 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY)HEXANAMIDE; 7 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY) N HYDROXYHEPTANAMIDE; 7 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY)HEPTANAMIDE; 8 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY) N HYDROXYOCTANAMIDE; 8 [4 (3,17 DIHYDROXY 13 METHYL 7,8,9,11,12,13,14,15,16,17 DECAHYDRO 6H CYCLOPENTA[A]PHENANTHREN 17 YL) 1H 1,2,3 TRIAZOL 1 YL] N (TRITYLOXY)OCTANAMIDE; ENDOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TAMOXIFEN; TAMOXIFEN TRIAZOLYLHYDROXAMIC ACID; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG CONFORMATION; DRUG CONJUGATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; NUCLEOTIDE SEQUENCE; PHARMACOPHORE; PROSTATE CANCER; TRIPLE NEGATIVE BREAST CANCER; VERO CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DRUG DISCOVERY; ESTROGEN RECEPTOR MODULATORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR DOCKING SIMULATION; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880856474     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400467w     Document Type: Article

References (61)

1. Lehrmann, H.; Pritchard, L. L.; Harel-Bellan, A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation Adv. Cancer Res. 2002, 86, 41-65
2. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies Nature Rev. Cancer 2001, 1 (3) 194-202
3. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nature Rev. Drug Discovery 2006, 5 (9) 769-784
4. Gryder, B. E.; Sodji, Q. H.; Oyelere, A. K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed Future Med. Chem. 2012, 4 (4) 505-524
5. Marks, P. A.; Xu, W. S. Histone Deacetylase Inhibitors: Potential in Cancer Therapy J. Cell. Biochem. 2009, 107 (4) 600-608
6. Gryder, B.; Nelson, C.; Shepard, S. Biosemiotic Entropy of the Genome: Mutations and Epigenetic Imbalances Resulting in Cancer Entropy 2013, 15 (1) 234-261
7. Park, S. Y.; Jun, J. A.; Jeong, K. T.; Heo, H. J.; Sohn, J. S.; Lee, H. Y.; Park, C. G.; Kang, J. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer Oncol. Rep. 2011, 25 (6) 1677-1681
8. Marks, P. A. Discovery and development of SAHA as an anticancer agent Oncogene 2007, 26 (9) 1351-1356
9. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R. W.; Gardner, E. R.; Figg, W. D.; Batest, S. E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors Expert Rev. Anticancer Ther. 2010, 10 (7) 997-1008
10. Schneider, B. J.; Kalemkerian, G. P.; Bradley, D.; Smith, D. C.; Egorin, M. J.; Daignault, S.; Dunn, R.; Hussain, M. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies Invest. New Drugs 2012, 30 (1) 249-257
11. Shah, M. H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M. Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors Clin. Cancer Res. 2006, 12 (13) 3997-4003
12. Ai, T.; Cui, H.; Chen, L. Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy Curr. Med. Chem. 2012, 19 (4) 475-487
13. Seo, S. Y. Multi-Targeted Hybrids Based on HDAC Inhibitors for Anti-Cancer Drug Discovery Arch. Pharm. Res. 2012, 35 (2) 197-200
14. Rao, R.; Balusu, R.; Fiskus, W.; Mudunuru, U.; Venkannagari, S.; Chauhan, L.; Smith, J. E.; Hembruff, S. L.; Ha, K.; Atadja, P.; Bhalla, K. N. Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells Mol. Cancer Ther. 2012, 11 (4) 973-983
15. Munster, P. N.; Lacevic, M.; Thomas, S.; Ismail-Khan, R.; Rugo, H.; Melisko, M.; Minton, S. E. Clinical Phase II Study of Vorinostat, a Hydroxamic Type Histone Deacetylase Inhibitor, in Combination with Tamoxifen To Reverse Acquired Hormone Resistance in Breast Cancer Patients Who Progressed on Hormone Therapy Cancer Res. 2009, 69 (24) 856S-856S
16. Ring, A.; Dowsett, M. Mechanisms of tamoxifen resistance Endocr.-Relat. Cancer 2004, 11 (4) 643-658
17. Speirs, V.; Malone, C.; Walton, D. S.; Kerin, M. J.; Atkin, S. L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients Cancer Res. 1999, 59 (21) 5421-5424
18. Sharma, D.; Saxena, N. K.; Davidson, N. E.; Vertino, P. M. Restoration of Tamoxifen Sensitivity in Estrogen Receptor-Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor Complexes Cancer Res. 2006, 66 (12) 6370-6378
19. Levin, E. R. Plasma membrane estrogen receptors Trends Endocrinol. Metab. 2009, 20 (10) 477-482
20. Cheng, S.-B.; Graeber, C. T.; Quinn, J. A.; Filardo, E. J. Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus Steroids 2011, 76 (9) 892-896
21. Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang, Y. Z.; Fan, Y. H. Non-Peptide Macrocyclic Histone Deacetylase Inhibitors J. Med. Chem. 2009, 52 (2) 456-468
22. Guerrant, W.; Patil, V.; Canzoneri, J. C.; Oyelere, A. K. Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors J. Med. Chem. 2012, 55 (4) 1465-1477
23. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton J. Med. Chem. 2010, 53 (16) 6100-6111
24. Patil, V.; Guerrant, W.; Chen, P. C.; Gryder, B.; Benicewicz, D. B.; Khan, S. I.; Tekwani, B. L.; Oyelere, A. K. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2010, 18 (1) 415-425
25. Huang, W.-J.; Chen, C.-C.; Chao, S.-W.; Yu, C.-C.; Yang, C.-Y.; Guh, J.-H.; Lin, Y.-C.; Kuo, C.-I.; Yang, P.; Chang, C.-I. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors Eur. J. Med. Chem. 2011, 46 (9) 4042-4049
26. Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform selectivity in histone deacetylase inhibitors Curr. Pharm. Des. 2008, 14 (6) 505-528
27. Chen, P. C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2008, 16 (9) 4839-4853
28. Cyrus, K.; Wehenkel, M.; Choi, E. Y.; Lee, H.; Swanson, H.; Kim, K. B. Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor-Targeting PROTACs ChemMedChem 2010, 5 (7) 979-985
29. Dao, K. L.; Sawant, R. R.; Hendricks, J. A.; Ronga, V.; Torchilin, V. P.; Hanson, R. N. Design, Synthesis, and Initial Biological Evaluation of a Steroidal Anti-Estrogen-Doxorubicin Bioconjugate for Targeting Estrogen Receptor-Positive Breast Cancer Cells Bioconjugate Chem. 2012, 23 (4) 785-795
30. Peng, K.-w.; Wang, H.; Qin, Z.; Wijewickrama, G. T.; Lu, M.; Wang, Z.; Bolton, J. L.; Thatcher, G. R. J. Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer Cells ACS Chem. Biol. 2009, 4 (12) 1039-1049
31. Nettles, K. W.; Bruning, J. B.; Gil, G.; O'Neill, E. E.; Nowak, J.; Hughs, A.; Kim, Y.; DeSombre, E. R.; Dilis, R.; Hanson, R. N.; Joachimiak, A.; Greene, G. L. Structural plasticity in the oestrogen receptor ligand-binding domain EMBO Rep. 2007, 8 (6) 563-568
32. Olmsted, S. L.; Tongcharoensirikul, P.; McCaskill, E.; Gandiaga, K.; Labaree, D.; Hochberg, R. B.; Hanson, R. N. Synthesis and evaluation of 17α- E -20-(heteroaryl)norpregn-1,3,5(10),20 tetraene-3,17β-diols [17α-(heteroaryl)vinyl estradiols] as ligands for the estrogen receptor-α ligand binding domain (ERα-LBD) Bioorg. Med. Chem. Lett. 2012, 22 (2) 977-979
33. Maximov, P. Y.; Myers, C. B.; Curpan, R. F.; Lewis-Wambi, J. S.; Jordan, V. C. Structure-Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen J. Med. Chem. 2010, 53 (8) 3273-3283
34. Burke, P. J.; Koch, T. H. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells J. Med. Chem. 2004, 47 (5) 1193-1206
35. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 41 (14) 2596-2599
36. Olofson, R. A.; Martz, J. T.; Senet, J. P.; Piteau, M.; Malfroot, T. A New Reagent For The Selective, High-Yield N -Dealkylation Of Tertiary-Amines-Improved Syntheses Of Naltrexone And Nalbuphine J. Org. Chem. 1984, 49 (11) 2081-2082
37. Bissantz, C.; Kuhn, B.; Stahl, M. A Medicinal Chemist's Guide to Molecular Interactions J. Med. Chem. 2010, 53 (14) 5061-5084
38. Li, M.-J.; Greenblatt, H. M.; Dym, O.; Albeck, S.; Pais, A.; Gunanathan, C.; Milstein, D.; Degani, H.; Sussman, J. L. Structure of Estradiol Metal Chelate and Estrogen Receptor Complex: The Basis for Designing a New Class of Selective Estrogen Receptor Modulators J. Med. Chem. 2011, 54 (10) 3575-3580
39. Thomas, C.; Gustafsson, J. A. The different roles of ER subtypes in cancer biology and therapy Nature Rev. Cancer 2011, 11 (8) 597-608
40. Fox, E. M.; Davis, R. J.; Shupnik, M. A. ER beta in breast cancer-onlooker, passive player, or active protector? Steroids 2008, 73 (11) 1039-1051
41. Wang, Z. Z.; Li, Y.; Ai, C. Z.; Wang, Y. H. In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using Statistical Methods and Molecular Docking with 2-Arylnaphthalenes and 2-Arylquinolines Int. J. Mol. Sci. 2010, 11 (9) 3434-3458
42. Allred, D. C.; Brown, P.; Medina, D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer Breast Cancer Res. 2004, 6 (6) 240-245
43. Sabnis, G. J.; Goloubeva, O.; Chumsri, S.; Nguyen, N.; Sukumar, S.; Brodie, A. M. H. Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole Cancer Res. 2011, 71 (5) 1893-1903
44. Yang, X.; Ferguson, A. T.; Nass, S. J.; Phillips, D. L.; Butash, K. A.; Wang, S. M.; Herman, J. G.; Davidson, N. E. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition Cancer Res. 2000, 60 (24) 6890-6894
45. Kreis, W.; Budman, D. R.; Calabro, A. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents Cancer Chemother. Pharmacol. 2001, 47 (1) 78-82
46. Lau, K.-M.; LaSpina, M.; Long, J.; Ho, S.-M. Expression of Estrogen Receptor (ER)-α and ER-β in Normal and Malignant Prostatic Epithelial Cells: Regulation by Methylation and Involvement in Growth Regulation Cancer Res. 2000, 60 (12) 3175-3182
47. Muller, P. Y.; Milton, M. N. The determination and interpretation of the therapeutic index in drug development Nature Rev. Drug Discovery 2012, 11 (10) 751-761
48. Owens, P. C.; Gill, P. G.; De Young, N. J.; Weger, M. A.; Knowles, S. E.; Moyse, K. J. Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells Biochem. Biophys. Res. Commun. 1993, 193 (2) 467-473
49. Sutherland, R. L.; Green, M. D.; Hall, R. E.; Reddel, R. R.; Taylor, I. W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle Eur. J. Cancer Clin. Oncol. 1983, 19 (5) 615-621
50. Qiu, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells Mol. Biol. Cell 2000, 11 (6) 2069-2083
51. Hirose, T.; Sowa, Y.; Takahashi, S.; Saito, S.; Yasuda, C.; Shindo, N.; Furuichi, K.; Sakai, T. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y Oncogene 2003, 22 (49) 7762-7773
52. Warrener, R.; Beamish, H.; Burgess, A.; Waterhouse, N. J.; Giles, N.; Fairlie, D.; Gabrielli, B. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints FASEB J. 2003, 17 (11) 1550-1552
53. Pujol, J. L.; von Pawel, J.; Tumolo, S.; Martoni, A.; Hearn, S.; Fields, S. Z.; Ross, G. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer Oncology 2001, 61 (Suppl 1) 47-54
54. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26
55. Dreaden, E. C.; Mwakwari, S. C.; Sodji, Q. H.; Oyelere, A. K.; El-Sayed, M. A. Tamoxifen-Poly(ethylene glycol)-thiol Gold Nanoparticle Conjugates: Enhanced Potency and Selective Delivery for Breast Cancer Treatment Bioconjugate Chem. 2009, 20 (12) 2247-2253
56. Pelekanou, V.; Kampa, M.; Kafousi, M.; Dambaki, K.; Darivianaki, K.; Vrekoussis, T.; Sanidas, E.; Tsiftsis, D. D.; Stathopoulos, E. N.; Castanas, E. Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol., Biomarkers Prev. 2007, 16 (10) 2016-2023
57. Taylor, J.; Rohatgi, P.; Spencer, H. T.; Doyle, D.; Azizi, B. Characterization of a molecular switch system that regulates gene expression in mammalian cells through a small molecule BMC Biotechnol. 2010, 10 (1) 15
58. Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31 (2) 455-461
59. Hooft, R. W. W.; Vriend, G.; Sander, C.; Abola, E. E. Errors in protein structures Nature 1996, 381 (6580) 272-272
60. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformatics 2006, 22 (2) 195-201
61. Kuiper, G.; Shughrue, P. J.; Merchenthaler, I.; Gustafsson, J. A. The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems Front. Neuroendocrinol. 1998, 19 (4) 253-286